Compare Hershey Co (HSY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs Recursion Pharmaceuticals Inc — how do they compare? Hershey Co trades at $162.46 (market cap $32.66B), while Recursion Pharmaceuticals Inc trades at $4.23 (market cap $2.14B). The key difference: Hershey Co is far larger — about 15.3× Recursion Pharmaceuticals Inc's market cap, and Hershey Co pays a 3.57% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hershey Co for 135 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| HSY | RXRX | |
|---|---|---|
Market Cap | $32.66B | $2.14B |
Volume | 1,578,237 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $236.28 | $6.79 |
52-Week Low | $157.61 | $2.84 |
Typical Hold Time | 135 Days | 22 Days |
Enterprise Value | $37.79B | $1.66B |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $160.34, down 0.29% on the day, with the stock showing bearish technical signals despite strong recent earnings beats. The company maintains solid profitability with a 12.24% net margin and 32.81% ROE, though 2025 net income declined to $883 million from prior years. Analyst consensus remains cautious with 65.72% hold ratings, but the $204.62 price target suggests 27.6% upside potential. Recent corporate developments include international leadership changes and ongoing brand investments to drive demand.
HSY presents a mixed investment case with attractive valuation upside but near-term headwinds. The stock's current price near support levels offers entry opportunity for dividend investors, with the recent dividend resumption signaling management confidence. However, commodity cost pressures and competitive threats in the consumer staples space create execution risks. Institutional ownership trends show mixed signals with both new positions and reductions in Q2 2026.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
